Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Oryzon Genomics, S.A.
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
June 11, 2026
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
June 2, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
May 13, 2026
ORYZON to Participate in Upcoming Events in May and June
April 29, 2026
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
March 25, 2026
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
March 23, 2026
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
March 12, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
February 27, 2026
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
February 24, 2026
1
2
Next Page
→